NCT02561195 A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years Status COMPLETED Phase PHASE2
NCT02554877 A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin Status COMPLETED Phase PHASE2
NCT02554812 A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Status TERMINATED Phase PHASE1/PHASE2
NCT02548949 Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ Status COMPLETED Phase N/A
NCT02546375 A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands Status COMPLETED Phase N/A
NCT02540187 Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients Status COMPLETED Phase N/A
NCT02539550 A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects Status COMPLETED Phase PHASE1
NCT02539368 Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease Status COMPLETED Phase N/A
NCT02537002 Single Dose Study of PF-05230907 in Healthy Japanese Subjects Status COMPLETED Phase PHASE1
NCT02535390 Action-Based Cognitive Remediation to Improve Vocational Outcomes in Depression Status COMPLETED Phase NA
NCT02534935 Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers. Status COMPLETED Phase PHASE2
NCT02534766 MISSION COPD - Modern Innovative SolutionS in Improving Outcomes iN COPD Status COMPLETED Phase N/A
NCT02534740 A Study Comparing Amounts of Tafamidis In The Blood With Or Without Food Status COMPLETED Phase PHASE1
NCT02533258 Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice Status COMPLETED Phase N/A
NCT02531698 A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years Status COMPLETED Phase PHASE2